CandlesenseCandlesense
PFE•benzinga•

Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%

Summary

Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 trial.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 30, 2025 by benzinga

← Back to PFE News
    Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50% | PFE Stock News | Candlesense